Immutep (IMMP)
NASDAQ:IMMP
Want to see IMMP full AI Analyst Report?
Top Page
Immutep
(NASDAQ:IMMP)
Select Model
Select Model
Rating:40Underperform
Price Target:
$0.44
▼(-78.53% Downside)
Action:DowngradedDate:04/16/26
The score is primarily held down by weak financial performance, including persistent losses and negative operating/free cash flow. Technicals add further pressure due to a broader downtrend and negative MACD, though near-oversold RSI/Stoch modestly offsets this. Valuation is also constrained by a negative P/E and no dividend yield data.
Positive Factors
Extended Cash Runway
A material cash balance plus a $20m upfront supports operations and funds strategic reassessment after the TACTI-004 wind-down. This increases near-to-medium term financial flexibility, reduces immediate financing pressure, and allows reallocation of capital to higher‑value programs or partnering.
Negative Factors
Persistent Unprofitability
Sustained negative gross, EBIT and net margins indicate the company is not generating operating profits and remains loss-making. Over multiple reporting periods this undermines shareholder equity returns and necessitates ongoing external funding or dilutive partnerships to sustain development.
Read all positive and negative factors
Positive Factors
Negative Factors
Extended Cash Runway
A material cash balance plus a $20m upfront supports operations and funds strategic reassessment after the TACTI-004 wind-down. This increases near-to-medium term financial flexibility, reduces immediate financing pressure, and allows reallocation of capital to higher‑value programs or partnering.
Read all positive factors
Immutep (IMMP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$63.00M
Dividend YieldN/A
Average Volume (3M)28.11M
Price to Earnings (P/E)―
Beta (1Y)2.21
Revenue GrowthN/A
EPS Growth-69.60%
CountryUS
Employees41
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.57
Shares Outstanding147,372,130
10 Day Avg. Volume77,504,184
30 Day Avg. Volume28,114,875
Financial Highlights & Ratios
PEG Ratio-0.32
Price to Book (P/B)2.53
Price to Sales (P/S)71.92
P/FCF Ratio-5.84
Enterprise Value/Market Cap0.31
Enterprise Value/Revenue2.44
Enterprise Value/Gross Profit-0.26
Enterprise Value/Ebitda-0.24
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)-0.32
Revenue Forecast (FY)$18.98M
Immutep Business Overview & Revenue Model
Company Description
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate...
How the Company Makes Money
Immutep’s business model is typical of a clinical-stage biotech: it primarily seeks to create value and generate cash through partnering its drug candidates rather than through product sales (as it does not have widely marketed, commercial product...
Immutep Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
45
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.92M | 5.04M | 3.84M | 3.51M | 170.37K | 3.86M |
| Gross Profit | -74.78M | -56.37M | -37.70M | 1.44M | -1.89M | -13.37M |
| EBITDA | -81.38M | -62.88M | -44.54M | -39.57M | -31.87M | -17.77M |
| Net Income | -83.92M | -61.43M | -42.72M | -39.90M | -32.21M | -29.90M |
Balance Sheet | ||||||
| Total Assets | 147.20M | 156.98M | 201.58M | 147.45M | 102.17M | 82.03M |
| Cash, Cash Equivalents and Short-Term Investments | 99.13M | 129.69M | 181.88M | 123.42M | 80.00M | 60.13M |
| Total Debt | 1.21M | 1.63M | 1.59M | 1.23M | 1.73M | 2.82M |
| Total Liabilities | 48.30M | 13.35M | 12.06M | 10.98M | 8.09M | 8.76M |
| Stockholders Equity | 98.90M | 143.64M | 189.52M | 136.47M | 94.08M | 73.27M |
Cash Flow | ||||||
| Free Cash Flow | -61.75M | -62.10M | -35.75M | -35.93M | -30.25M | -17.66M |
| Operating Cash Flow | -61.63M | -62.05M | -34.82M | -35.88M | -30.23M | -17.64M |
| Investing Cash Flow | 58.95M | -38.53M | -21.02M | -31.00K | -22.91K | -15.60K |
| Financing Cash Flow | -208.44K | -525.12K | 95.18M | 76.04M | 50.33M | 52.68M |
Immutep Technical Analysis
Neutral
2.04
Price Trends
1.57
Negative
2.11
Negative
1.94
Negative
Market Momentum
-0.28
Negative
37.17
Neutral
36.28
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMMP, the sentiment is Neutral. The current price of 2.04 is above the 20-day moving average (MA) of 0.38, above the 50-day MA of 1.57, and above the 200-day MA of 1.94, indicating a neutral trend. The MACD of -0.28 indicates Negative momentum. The RSI at 37.17 is Neutral, neither overbought nor oversold. The STOCH value of 36.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IMMP.
Immutep Risk Analysis
Immutep disclosed 52 risk factors in its most recent earnings report. Immutep reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Immutep Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $282.04M | -7.16 | -69.63% | ― | 76.18% | -109.46% | |
49 Neutral | $347.64M | -6.10 | -300.94% | ― | ― | ― | |
47 Neutral | $486.48M | -4.54 | -90.52% | ― | -40.98% | 42.18% | |
44 Neutral | $245.04M | -1.05 | 279.62% | ― | ― | ― | |
40 Underperform | $63.00M | -3.51 | -69.20% | ― | ― | -69.60% |
* Healthcare Sector Average
IMMP
Immutep
0.44
-1.49
-77.10%
CLLS
Cellectis SA
3.95
2.43
159.87%
RNAC
Cartesian Therapeutics
8.34
-1.81
-17.83%
SLN
Silence Therapeutics
7.36
3.66
98.92%
LYEL
Lyell Immunopharma
20.85
12.43
147.62%
Immutep Corporate Events
Immutep Halts Key Lung Cancer Phase III Trial but Maintains Strong Cash Position and Pipeline Progress
May 1, 2026
In March 2026, Immutep discontinued its Phase III TACTI-004 trial in first-line non-small cell lung cancer after an interim futility analysis showed patients on eftilagimod alfa with KEYTRUDA and chemotherapy underperformed the placebo combination...
Immutep Faces Nasdaq Bid-Price Warning but Retains Dual Listings
May 1, 2026
On April 30, 2026, Immutep Limited disclosed that it received a notice from Nasdaq stating its American Depositary Shares no longer meet the exchange’s minimum bid price requirement of US$1.00, after trading below that threshold for 30 conse...
Immutep Wins FDA Orphan Drug Status for Eftilagimod Alfa in Soft Tissue Sarcoma
Apr 16, 2026
On April 15, 2026, Immutep announced that the U.S. Food and Drug Administration granted Orphan Drug Designation to its lead candidate eftilagimod alfa for treating soft tissue sarcoma, a rare cancer with high unmet need. The status, which can prov...
Immutep Advances First-in-Class LAG-3 Agonist IMP761 With Positive Phase I Progress
Mar 20, 2026
On March 19, 2026, Immutep reported positive progress from its first-in-human Phase I trial of IMP761, a first-in-class LAG-3 agonist antibody for autoimmune diseases, in healthy participants. The company has completed the single ascending dose ph...
Immutep Halts Pivotal Lung Cancer Trial After Futility Review, Extends Cash Runway
Mar 16, 2026
On March 13, 2026, Immutep said an Independent Data Monitoring Committee recommended halting its TACTI-004 Phase III trial of eftilagimod alfa in first-line non-small cell lung cancer after a planned interim futility analysis. The company will sto...
Immutep Doubles Half-Year Loss as R&D Spend Rises Despite New Dr. Reddy’s Funding
Feb 26, 2026
On 25 February 2026, Immutep released its Appendix 4D half-year financial report for the period ended 31 December 2025, showing total revenue and other income up 6% to A$7.7 million, supported by A$4.1 million in new collaboration revenue from Dr....
Immutep Reaches 50% Enrolment in Global Phase III Lung Cancer Trial
Feb 10, 2026
On February 6, 2026, Immutep announced it had reached 50% of target enrolment in its global TACTI-004 (KEYNOTE-F91) Phase III trial in first-line advanced or metastatic non-small cell lung cancer, with 378 patients now enrolled worldwide. The tria...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.